|
KMID : 1149120210180010001
|
|
Journal of the Korean Society for Psoriasis
2021 Volume.18 No. 1 p.1 ~ p.4
|
|
|
Updates on the Safety of Interleukin-17 Inhibitors
|
|
Son Joon-Ho
Bang Chul-Hwan
|
|
|
Abstract
|
|
|
|
Psoriasis is a chronic, recurrent inflammatory skin disease. Recently, it has been found that Th17 cells and IL-17 are critical in the pathogenesis of psoriasis, and biologics which targeted anti IL-17 therapies made a dramatic improvement in treating psoriasis. At the same time, safety concerns about the biologics have also been raised. In this paper, we reviewed the safety concerns of secukinumab and ixekizumab, which are IL-17A antagonist used in Korea. The most common adverse effect in both biologics was upper respiratory infection including nasopharyngitis. There have also been concerns about tuberculosis, herpes zoster, and inflammatory bowel disease due to its immunosuppressive mechanism. However, reviewing the recent articles, neither biologics have shown to increase the risk of tuberculosis, herpes zoster, and inflammatory bowel disease. Nevertheless, paradoxical reactions in IL-17A antagonist have been reported, including aggravation of inflammatory bowel disease and eczema. Due to the lack of clinical data and the high prevalence of tuberculosis in Korea, use of IL-17A antagonist in active tuberculosis patients should still be cautious.
|
|
|
KEYWORD
|
|
|
Herpes zoster, IL-17 inhibitor, Inflammatory bowel disease, Psoriasis, Tuberculosis reactivation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|